Table 1: CANHEART indicators of primary prevention performance.

Domain	Subject area; indicator
	Smoking	Obesity	Hypertension	Diabetes	Dyslipidemia	Atrial fibrillation	Access to primary care
Prevalence	Prevalence of smoking	Prevalence of obesity	Prevalence of hypertension	Prevalence of diabetes	Prevalence of high lipid levels (e.g., total cholesterol ≥ 5.2 mmol/L)	Prevalence of atrial fibrillation	% of patients who have visited a primary care provider
Screening	NA	% of patients with height and weight measured	% of patients with blood pressure measured	% of patients aged ≥ 40 yr who have had full fasting blood glucose or HbA1c screening test in previous 36 mo	% of men aged ≥ 40 yr and women aged ≥ 50 yr who have had full lipid profile in previous 5 yr	NA	NA
Management	% of smokers who received smoking cessation counselling	NA	% of patients with hypertension taking ≥ 1 antihypertensive medication OR Mean number of antihypertensive medications taken among patients with treated hypertension	% of patients with diabetes taking antidiabetic medications % of patients with diabetes aged ≥ 55 yr taking ACE inhibitors/ARBs % of patients with diabetes aged ≥ 40 yr taking statins	% of primary prevention patients at high risk (e.g., LDL-C level > 5.0, high Framingham risk score, diabetic) taking statins	% of patients with atrial fibrillation taking warfarin or direct oral anticoagulants	Mean no. of primary care visits per yr (e.g., for hypertension, diabetes)
Intermediate outcomes	NA	NA	% of patients with hypertension with measured blood pressure control (< 140 mm Hg systolic and < 90 mm Hg diastolic)* OR Rate of emergency department visits for hypertension among patients with hypertension	% of patients with diabetes with HbA1c level controlled (≤ 7%)†	% of patients taking statins for primary prevention who have lipid levels controlled (LDL-C ≤ 2.0 mmol/L)	% of time in therapeutic range (INR 2-3) among patients with atrial fibrillation taking warfarin	NA

Note: ACE = angiotensin-converting-enzyme inhibitor, ARB = angiotensin receptor blockers, HbA_1c = hemoglobin A_1c, INR = international normalized ratio, LDL-C = low-density lipoprotein cholesterol, NA = not applicable.

*Patients with diabetes should be treated to target blood pressures of < 130 mm Hg systolic and < 80 mm Hg diastolic.²²

†A less stringent hemoglobin A_1c target of 7.1%-8.5% may be used in certain patients with diabetes such as those with limited life expectancy and those with high levels of functional dependency.²³